. 2025 Aug 21;15:30778. doi: 10.1038/s41598-025-05025-w

Table 1.

Multivariate cox hazard regression models of prognostically significant DNA and RNA genes associated with radiotherapy and chemo-radiotherapy.

	CLTCL1^a		RGL3^a
Variable	DNA	RNA	DNA	RNA
Gene	3.2(0.001^b)	1.5(0.08)	2.6(0.01^b)	0.3(0.05)
Age	1(0.1)	1(0.04^b)	1(0.15)	1(0.04^b)
AJCC pathologic stage
Stage 1 and 2 vs. 3 and 4	2.8(0.01^b)	2.7(0.01^b)	2.6(0.02^b)	2.5(0.02^b)
Lymphovascular invasion
Absence vs. presence	1.5(0.08)	1.6(0.07)	1.7(0.04^b)	1.7(0.03^b)
Perineural invasion
Absence vs. presence	1.9(0.01^b)	1.8(0.02^b)	1.9(0.01^b)	1.7(0.04^b)
Treatment modality
Surgery vs. surgery + RT	0.5(0.02^b)	0.6(0.06)	0.5(0.03^b)	0.6(0.1)
Surgery vs. surgery + CCRT	0.7(0.18)	0.7(0.19)	0.7(0.2)	0.7(0.32)

	H3C12^a		JPH3^a
Variable	DNA	RNA	DNA	RNA
Gene	18.5(0.001^b)	2.3(0.001^b)	3.2(0.01^b)	0.4(0.02^b)
Age	1(0.1)	1(0.13)	1(0.08)	1(0.02^b)
AJCC pathologic stage
Stage 1 and 2 vs. 3 and 4	2.8(0.01^b)	2.1(0.05)	2.9(0.01^b)	2.6(0.01^b)
Lymphovascular invasion
Absence vs. presence	1.6(0.06)	1.6(0.06)	1.6(0.07)	1.7(0.03^b)
Perineural invasion
Absence vs. presence	1.8(0.02^b)	2.3(0.002^b)	2(0.01^b)	1.8(0.02^b)
Treatment modality
Surgery vs. surgery + RT	0.5(0.03^b)	0.5(0.02^b)	0.5(0.02^b)	0.6(0.1)
Surgery vs. surgery + CCRT	0.7(0.19)	0.6(0.1)	0.6(0.12)	0.9(0.61)

	SLC35G5^a		GARS1^a
Variable	DNA	RNA	DNA	RNA
Gene	2.2(0.001^b)	0.5(0.048^b)	2.6(0.01^b)	1.5(0.06)
Age	1(0.14)	1(0.05)	1(0.12)	1(0.04^b)
AJCC pathologic stage
Stage 1 and 2 vs. 3 and 4	2.6(0.01^b)	2.3(0.03^b)	2.7(0.01^b)	2.6(0.01^b)
Lymphovascular invasion
Absence vs. presence	1.7(0.03^b)	1.5(0.08)	1.7(0.04^b)	1.7(0.04^b)
Perineural invasion
Absence vs. presence	2.1(0.003^b)	1.9(0.01^b)	1.7(0.03^b)	1.8(0.02^b)
Treatment modality
Surgery vs. surgery + RT	0.6(0.05)	0.6(0.12)	0.5(0.01^b)	0.5(0.04^b)
Surgery vs. surgery + CCRT	0.7(0.23)	0.7(0.19)	0.6(0.12)	0.7(0.21)

All six genes are reported as hazard ratios (p-values) in multivariate Cox analyses, adjusted for other prognostic factors (n = 188 and 185, respectively).

AJCC American Joint Committee on Cancer, RT radiotherapy, CCRT concurrent chemotherapy and radiotherapy, HR hazard ratio.

^a The statistical significance of fitted model of Cox proportional hazard ratio was calculated by likelihood ratio test (p < 0.00001).

^b p < 0.05, multivariate Cox regression analysis.